Increased levels of inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-6 (IL-6) may play a role in depression. Mild depressive-like symptoms can be induced in humans through activation of the innate immune system with endotoxin. Whether preventive treatment with antidepressants can reduce endotoxin-induced symptoms has never been tested. In a double-blind, randomized, placebocontrolled, cross-over study, we administered intravenous low-dose endotoxin (0.8 ng/kg) or placebo to 11 healthy subjects who had received oral pre-treatment with citalopram (10 mg twice a day) or placebo for 5 days. The Montgomery-Åsberg Depression Rating Scale, the State and Trait Anxiety Inventory, and a visual analog scale were used to measure depressive and anxiety symptoms and social anhedonia. Serum levels of TNF and IL-6 were measured with immunoassays. Compared to placebo, endotoxin administration increased serum levels of TNF and IL-6, and caused mild depressive-like symptoms, in particular lassitude and social anhedonia. While citalopram pre-treatment had no effect on the innate immune response to endotoxin, it reduced the endotoxin-induced MADRS total score by 50%, with a moderate effect size (Cohen's d = 0.5). Most of the MADRS total score was due to the lassitude item, and citalopram pre-treatment specifically reduced endotoxin-induced lassitude with a large effect size (Cohen's d = 0.9). These results suggest that subchronic pre-treatment with the serotonin-reuptake inhibitor citalopram blunts mood symptoms induced by acute immune system activation with endotoxin without inhibiting the peripheral immune response.
Introduction
The pathogenesis of depression is incompletely understood. Immune abnormalities, e.g., increased levels of inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-6 (IL-6) may play a role (Dowlati et al., 2010) . This is supported by the fact that experimentally elevating circulating levels of TNF and IL-6, with e.g., endotoxin, can produce depressive symptoms (Reichenberg et al., 2001; Eisenberger et al., 2009; DellaGioia and Hannestad, 2010) . Endotoxin administration in humans has been used to study the systemic response to innate immune system activation because doses of 2-4 ng/kg cause increases in serum TNF and IL-6 levels similar to those seen in sepsis (Michie et al., 1988; Suffredini et al., 1999) . Lower doses (0.4-0.8 ng/kg) cause less pronounced increases in TNF and IL-6 levels, and mild depressive symptoms (Reichenberg et al., 2001; Eisenberger et al., 2009 ). Rodent data suggest that depressive behaviors produced by immune activation depend on serotonin availability (O'Connor et al., 2009) . Consistent with this, depressive symptoms that occur in the context of interferon-alpha (IFN-a) treatment are influenced by polymorphisms in the serotonin transporter gene (Bull et al., 2009; Lotrich et al., 2009 ) and can be prevented and treated with serotonin-reuptake inhibitor (SRI) antidepressants (Raison et al., 2007; Kraus et al., 2008) . No information is available on the effect of serotonin reuptake inhibition on endotoxin-induced depressive symptoms in humans. The goal of this study was to determine whether pre-treatment with citalopram could reduce depressive symptoms produced by acute administration of low-dose endotoxin.
Methods

Design
This is a double-blind, randomized, placebo-controlled, threeway cross-over study in which each subject received oral placebo pre-treatment followed by intravenous (i.v.) placebo administration (Pbo-Pbo condition), oral placebo pre-treatment followed by i.v. endotoxin (Pbo-End condition), and oral pre-treatment with citalopram followed by i.v. endotoxin (Cit-End condition). Each study day was separated by 2 weeks.
Subjects
Eleven healthy subjects (five women; mean age 32 ± 9 years) were enrolled. Eligibility was based on medical and psychiatric his-0889-1591/$ -see front matter Ó 2010 Elsevier Inc. All rights reserved. doi:10.1016/j.bbi.2010.10.013
